MCIM
MRTX

Meadow Creek Investment Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Meadow Creek Investment Management’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$24K Hold
308
– – ﹤0.01% 1312
2019
Q2 		$32K Hold
308
– – ﹤0.01% 1305
2019
Q1 		$23K Buy
+308
New +$21K ﹤0.01% 1307

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Meadow Creek Investment Management's MRTX Position: Q3 2019 in Review

Meadow Creek Investment Management held its Mirati Therapeutics, Inc. Common Stock (MRTX) position steady in Q3 2019 at 308 shares worth $24K. The position accounts for ﹤0.01% of the portfolio, ranked #1312.

Meadow Creek Investment Management first reported a position in MRTX in Q1 2019 and has held it in 3 quarters since. The position peaked at $32K in Q2 2019. 177 funds tracked by Wall St. Rank hold MRTX as of Q3 2019.

  • Meadow Creek Investment Management held 308 shares of Mirati Therapeutics, Inc. Common Stock worth $24K as of Q3 2019.
  • Meadow Creek Investment Management left its Mirati Therapeutics, Inc. Common Stock share count unchanged in Q3 2019.
  • Mirati Therapeutics, Inc. Common Stock made up ﹤0.01% of Meadow Creek Investment Management's portfolio in Q3 2019, its #1312 holding.
  • Meadow Creek Investment Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2019 and has held it in 3 quarters since.
  • Meadow Creek Investment Management's Mirati Therapeutics, Inc. Common Stock position peaked at $32K in Q2 2019.
  • 177 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q3 2019.

Based on Meadow Creek Investment Management's 13F filing for Q3 2019, filed 14 Nov 2019.